Showing 4841-4850 of 10503 results for "".
- Novel Jasmonate Compound Takes On Fine Wrinkles, Poreshttps://practicaldermatology.com/news/novel-jasmonate-compound-takes-on-fine-wrinkles-pores/2458704/The active ingredient in Lancome’s Visionnaire family of products safely and effectively helps improve the appearance of fine wrinkles, skin tone and pores
- Age-related Fibroblast Changes Drive Melanoma in Males, Study Sayshttps://practicaldermatology.com/news/age-related-fibroblast-changes-drive-melanoma-males-study-says/2468115/Age-related changes in fibroblasts contribute to development of aggressive, treatment-resistant melanoma in males, according to a Johns Hopkins Kimmel Cancer Center study published in Cell. The authors of the study, Dr. Ashani Weeraratna and colleagues, had previously shown in studies that
- Mount Sinai Wins $1.3M Grant to Expand Skin Biology Research Training Programhttps://practicaldermatology.com/news/mount-sinai-wins-13m-grant-to-expand-skin-biology-research-training-program/2461643/The Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai will expand its research training program in skin biology with support from a five-year, $1.3 million T32 grant from the National Institutes of Health (NIH) and the National Institute of Arth
- Avero Diagnostics Launches Test for Early-Stage Melanoma Progressionhttps://practicaldermatology.com/news/avero-diagnostics-launches-test-for-early-stage-melanoma-progression/2461541/Avero Diagnostics announced the US launch of AMBLor, a laboratory test for the identification of early-stage melanomas at low risk of progression. AMBLor technology identifies the presence of two prognostic biomarker proteins, AMBRA1 and loricrin, in the skin overlying the tumor, a
- New York City's Mount Sinai Launches Melanoma and Skin Cancer Centerhttps://practicaldermatology.com/news/new-york-citys-mount-sinai-launches-melanoma-and-skin-cancer-center/2460777/Mount Sinai received a second $10 million gift from the Waldman Family to open the Kimberly and Eric J. Waldman Melanoma and Skin Cancer Center at Mount Sinai. Housed within the Kimberly and Eric J. Waldman Department of Dermatology at the May
- Two New Studies Suggest Age Is A Primary Determinant Of Melanoma Treatment Resistancehttps://practicaldermatology.com/news/two-new-studies-suggest-age-is-a-primary-determinant-of-melanoma-treatment-resistance/2460595/Age is a primary factor in treatment response in animal and laboratory models of melanoma cells, according to two new studies. The new findings by Johns Hopkins Kimmel Cancer Center and
- Researchers Identify Cause of Aggressive SCCs in Recessive Dystrophic Epidermolysis Bullosahttps://practicaldermatology.com/news/researchers-identify-cause-of-aggressive-sccs-in-recessive-dystrophic-epidermolysis-bullosa/2457636/Immune system-related enzymes contribute significantly to the development of aggressive and fatal squamous cell carcinomas early in the life of individuals with recessive dystrophic epidermolysis bullosa (RDEB), an international team of scientists led by researchers at the Sidney Kimmel Canc
- New UK Data Raises Concerns on Fusidic Acid Resistance in Pediatric Patientshttps://practicaldermatology.com/news/regional-uk-data-raises-alarm-on-fusidic-acid-resistance-in-pediatric-patients/2484590/A recent UK study showed a shift in antimicrobial resistance patterns in Staphylococcus aureus (S. aureus) isolates associated with atopic dermatitis (AD), which the authors said raised concerns about the use of topical fusidic acid.
- Hemoglobin Discovered in the Epidermishttps://practicaldermatology.com/news/hemoglobin-discovered-in-the-epidermis/2462140/Hemoglobin is present in the epidermis, according to new research that sheds light on the skin's protective properties. For the first time,reesearchers discovered the hemoglobin α protein in human and mouse keratinocytes of the epidermis
- Arcutis’ ZORYVE Now in Preferred Position on National Formularies for CVS Caremarkhttps://practicaldermatology.com/news/arcutis-zoryve-now-in-preferred-position-on-national-formularies-for-cvs-caremark/2461868/Arcutis Biotherapeutics, Inc.’s ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis, including intertriginous psoriasis in adults and adolescents, is now covered as a preferred tier product on national formularies for CVS Caremar